{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:43:32Z","timestamp":1789710212971,"version":"4.0.1"},"reference-count":92,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100013252","name":"TG Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013252","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.clml.2023.07.011","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T15:01:27Z","timestamp":1690383687000},"page":"697-704","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["SOHO State of the Art Updates and Next Questions: Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia"],"prefix":"10.1016","volume":"23","author":[{"given":"Saumya","family":"Easaw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawyon","family":"Ezzati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine C.","family":"Coombs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clml.2023.07.011_bib0001","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2023.07.011_bib0002","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am J Hematol"},{"issue":"26","key":"10.1016\/j.clml.2023.07.011_bib0003","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clml.2023.07.011_bib0004","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv"},{"issue":"29","key":"10.1016\/j.clml.2023.07.011_bib0005","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci USA."},{"issue":"1","key":"10.1016\/j.clml.2023.07.011_bib0006","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.clml.2023.07.011_bib0007","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","article-title":"Single-agent ibrutinib in treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience","volume":"131","author":"O'Brien","year":"2018","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.clml.2023.07.011_bib0008","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2023.07.011_bib0009","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/leu.2017.175","article-title":"Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL\/SLL","volume":"32","author":"Brown","year":"2018","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.clml.2023.07.011_bib0010","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clml.2023.07.011_bib0011","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.clml.2023.07.011_bib0012","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3324\/haematol.2018.192328","article-title":"Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2","volume":"103","author":"Barr","year":"2018","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.clml.2023.07.011_bib0013","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2023.07.011_bib0014","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11523-021-00857-8","article-title":"Bruton tyrosine kinase inhibitors in B-Cell malignancies: their use and differential features","volume":"17","author":"Shirley","year":"2022","journal-title":"Target Oncol"},{"key":"10.1016\/j.clml.2023.07.011_bib0015","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221101697","article-title":"The potential of pirtobrutinib in multiple B-cell malignancies","volume":"13","author":"Jensen","year":"2022","journal-title":"Ther Adv Hematol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.07.011_bib0016","first-page":"4060","article-title":"Understanding ibrutinib treatment discontinuation patterns for chronic lymphocytic leukemia","volume":"130","author":"Sharman","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2023.07.011_bib0017","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2023.07.011_bib0018","unstructured":"Ibrutinib treatment in the first-line setting for patients with.... EHA Library. Ghia P. 2021; 325396. Available from: https:\/\/library.ehaweb.org\/eha\/2021\/eha2021-virtual-congress\/325396\/paolo.ghia.ibrutinib.treatment.in.the.first-line.setting.for.patients.with.html?f=listing%3D3%2Abrowseby%3D8%2Asortby%3D1%2Amedia%3D1"},{"issue":"10232","key":"10.1016\/j.clml.2023.07.011_bib0019","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.clml.2023.07.011_bib0020","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","article-title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia","volume":"36","author":"Sharman","year":"2022","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.clml.2023.07.011_bib0021","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.19.03355","article-title":"ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"38","author":"Ghia","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2023.07.011_bib0022","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.1097\/HS9.0000000000000801","article-title":"Acalabrutinib versus investigator's choice in relapsed\/refractory chronic lymphocytic leukemia: final ASCEND trial results","volume":"6","author":"Ghia","year":"2022","journal-title":"HemaSphere"},{"issue":"31","key":"10.1016\/j.clml.2023.07.011_bib0023","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.clml.2023.07.011_bib0024","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of bruton's tyrosine kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/j.clml.2023.07.011_bib0025","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2019001160","article-title":"Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2023.07.011_bib0026","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1200\/JCO.22.00510","article-title":"Zanubrutinib versus ibrutinib in relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: interim analysis of a randomized phase III trial","volume":"41","author":"Hillmen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2023.07.011_bib0027","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2023.07.011_bib0028","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.clml.2023.07.011_bib0029","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.3324\/haematol.2020.259432","article-title":"Zanubrutinib monotherapy for patients with treatment na\u00efve chronic lymphocytic leukemia and 17p deletion","volume":"106","author":"Tam","year":"2020","journal-title":"Haematologica"},{"issue":"Supp 1","key":"10.1016\/j.clml.2023.07.011_bib0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-134280","article-title":"Efficacy and Safety of zanubrutinib in patients with treatment-na\u00efve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): follow-up results from arm C of the SEQUOIA (BGB-3111-304) trial","volume":"136","author":"Brown","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2023.07.011_bib0031","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1111\/cas.13983","article-title":"Phase I study of tirabrutinib (ONO-4059\/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan","volume":"110","author":"Munakata","year":"2019","journal-title":"Cancer Sci"},{"issue":"4","key":"10.1016\/j.clml.2023.07.011_bib0032","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1182\/blood-2015-08-664086","article-title":"A phase 1 clinical trial of the selective BTK inhibitor ONO\/GS-4059 in relapsed and refractory mature B-cell malignancies","volume":"127","author":"Walter","year":"2016","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.clml.2023.07.011_bib0033","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1182\/blood-2017-02-765115","article-title":"Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO\/GS-4059","volume":"129","author":"Walter","year":"2017","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.clml.2023.07.011_bib0034","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/s41375-019-0658-7","article-title":"Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS\/ONO-4059)","volume":"34","author":"Rule","year":"2020","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.clml.2023.07.011_bib0035","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1111\/cas.14561","article-title":"A multicenter, open-label, phase II study of tirabrutinib (ONO\/GS-4059) in patients with Waldenstr\u00f6m's macroglobulinemia","volume":"111","author":"Sekiguchi","year":"2020","journal-title":"Cancer Sci"},{"issue":"1","key":"10.1016\/j.clml.2023.07.011_bib0036","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/neuonc\/noaa145","article-title":"Phase I\/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed\/refractory primary central nervous system lymphoma","volume":"23","author":"Narita","year":"2021","journal-title":"Neuro Oncol"},{"issue":"12","key":"10.1016\/j.clml.2023.07.011_bib0037","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1158\/1078-0432.CCR-19-3504","article-title":"Phase Ib Study of Tirabrutinib in combination with idelalisib or entospletinib in previously treated chronic lymphocytic leukemia","volume":"26","author":"Danilov","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2023.07.011_bib0038","unstructured":"ONO PHARMA USA's Tirabrutinib Receives Orphan Drug Designation from the FDA for the Treatment of Primary Central Nervous System Lymphoma. 2023. Available from: https:\/\/www.prnewswire.com\/news-releases\/ono-pharma-usas-tirabrutinib-receives-orphan-drug-designation-from-the-fda-for-the-treatment-of-primary-central-nervous-system-lymphoma-301779681.html"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.07.011_bib0039","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-134531","article-title":"Updated results from the phase II study of orelabrutinib monotherapy in Chinese patients with relapsed or refractory chronic lymphocytic leukemia\/small cell leukemia","volume":"136","author":"Xu","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2023.07.011_bib0040","first-page":"571","article-title":"Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1\/2, open-label, multicenter, single-arm study","volume":"98","author":"Deng","year":"2023","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.07.011_bib0041","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood-2021-145911","article-title":"The selective bruton tyrosine kinase (BTK) inhibitor TG-1701 as monotherapy and in combination with ublituximab and umbralisib (U2) in patients with B-cell malignancies","volume":"138","author":"Cheah","year":"2021","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.07.011_bib0042","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2020-138896","article-title":"A once daily, oral, triple combination of BTK inhibitor, mTOR inhibitor and IMiD for treatment of relapsed\/refractory richter's transformation and de novo diffuse large B-cell lymphoma","volume":"136","author":"Mato","year":"2020","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.07.011_bib0043","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1182\/blood-2019-126192","article-title":"A phase Ia\/Ib study exploring the synthetic lethality of the orally administered novel BTK inhibitor, Dtrmwxhs-12 (DTRM-12), in combination with everolimus and pomalidomide in patients with relapsed\/refractory CLL, DLBCL or other B-cell lymphomas","volume":"134","author":"Mato","year":"2019","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.clml.2023.07.011_bib0044","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.clml.2023.07.011_bib0045","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMc1402716","article-title":"Ibrutinib resistance in chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"S2","key":"10.1016\/j.clml.2023.07.011_bib0046","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/hon.3164_163","article-title":"Characterization of mechanisms of resistance in previously treated chronic lymphocytic leukemia (CLL) from a head-to-head trial of acalabrutinib versus ibrutinib","volume":"41","author":"Woyach","year":"2023","journal-title":"Hematol Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.07.011_bib0047","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2019-127674","article-title":"Resistance to acalabrutinib in CLL is mediated primarily by BTK mutations","volume":"134","author":"Woyach","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.07.011_bib0048","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/blood-2019-125488","article-title":"BTK Leu528Trp - a potential secondary resistance mechanism specific for patients with chronic lymphocytic leukemia treated with the next generation BTK inhibitor zanubrutinib","volume":"134","author":"Handunnetti","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2023.07.011_bib0049","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.18162","article-title":"A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed\/refractory B-cell malignancies","volume":"198","author":"Song","year":"2022","journal-title":"Br J Haematol"},{"issue":"20","key":"10.1016\/j.clml.2023.07.011_bib0050","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.1182\/bloodadvances.2022008325","article-title":"Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance","volume":"6","author":"Blombery","year":"2022","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.07.011_bib0051","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1182\/blood-2022-170985","article-title":"Novel BTK mutations conferring resistance to the second-generation, irreversible BTK inhibitor orelabrutinib (ICP-022)","volume":"140","author":"Zhu","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2023.07.011_bib0052","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid"},{"issue":"14","key":"10.1016\/j.clml.2023.07.011_bib0053","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1158\/1078-0432.CCR-22-2779","article-title":"Outcomes in patients with high-risk features after fixed-duration ibrutinib plus venetoclax: phase II CAPTIVATE Study in first-line chronic lymphocytic leukemia","volume":"29","author":"Allan","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"33","key":"10.1016\/j.clml.2023.07.011_bib0054","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.2217\/fon-2022-0456","article-title":"MAJIC: a phase III trial of acalabrutinib\u00a0+\u00a0venetoclax versus venetoclax\u00a0+\u00a0obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"18","author":"Ryan","year":"2022","journal-title":"Future Oncol"},{"issue":"5","key":"10.1016\/j.clml.2023.07.011_bib0055","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/jth.13651","article-title":"Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies","volume":"15","author":"Shatzel","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"14","key":"10.1016\/j.clml.2023.07.011_bib0056","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-16-1446","article-title":"Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells","volume":"23","author":"Patel","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clml.2023.07.011_bib0057","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/hematology.2020000118","article-title":"Managing toxicities of Bruton tyrosine kinase inhibitors","volume":"2020","author":"Lipsky","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"8","key":"10.1016\/j.clml.2023.07.011_bib0058","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3390\/jpm11080764","article-title":"Non-Covalent BTK Inhibitors-The New BTKids on the Block for B-Cell Malignancies","volume":"11","author":"Lewis","year":"2021","journal-title":"J Pers Med"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.07.011_bib0059","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1182\/blood-2019-124362","article-title":"LOXO-305: Targeting C481S Bruton Tyrosine Kinase in Patients with Ibrutinib-Resistant CLL","volume":"134","author":"Naeem","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.07.011_bib0060","doi-asserted-by":"crossref","unstructured":"Goldberg AD, M Ohanian, PB. Koller A Phase 1a\/b dose escalation study of the FLT3\/BTK inhibitor luxeptinib (CG-806) in patients with relapsed or refractory acute myeloid leukemia. 2022;140 (Suppl 1):6220\u20136221","DOI":"10.1182\/blood-2022-167759"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.07.011_bib0061","doi-asserted-by":"crossref","first-page":"6498","DOI":"10.1182\/blood-2022-163683","article-title":"A phase 1a\/b dose escalation study of the BTK\/FLT3 inhibitor luxeptinib in patients with relapsed or refractory B-cell malignancies","volume":"140","author":"Samaniego","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2023.07.011_bib0062","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3324\/haematol.2021.279158","article-title":"Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase","volume":"107","author":"Aslan","year":"2022","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.clml.2023.07.011_bib0063","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1182\/blood.2021011516","article-title":"Evaluation of vecabrutinib as a model for noncovalent BTK\/ITK inhibition for treatment of chronic lymphocytic leukemia","volume":"139","author":"Jebaraj","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2023.07.011_bib0064","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3324\/haematol.2021.280061","article-title":"Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies","volume":"107","author":"Allan","year":"2022","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.07.011_bib0065","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood-2019-126286","article-title":"Ongoing results of a phase 1B\/2 dose-escalation and cohort-expansion study of the selective, noncovalent, reversible Bruton's tyrosine kinase inhibitor, vecabrutinib, in B-cell malignancies","volume":"134","author":"Allan","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.07.011_bib0066","unstructured":"Safety, PK, PD, and antitumor activity of vecabrutinib (SNS-062) in B lymphoid cancers. ClinicalTrials.gov Identifier: NCT03037645. 2023. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03037645?term=vecabrutinib&draw=2&rank=1"},{"issue":"10","key":"10.1016\/j.clml.2023.07.011_bib0067","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/art.41811","article-title":"Efficacy, safety, and pharmacodynamic effects of the Bruton's tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled trial","volume":"73","author":"Isenberg","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"16","key":"10.1016\/j.clml.2023.07.011_bib0068","doi-asserted-by":"crossref","first-page":"13023","DOI":"10.18632\/oncotarget.24310","article-title":"First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL","volume":"9","author":"Byrd","year":"2018","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.clml.2023.07.011_bib0069","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1158\/2159-8290.CD-17-1409","article-title":"The BTK Inhibitor ARQ 531 targets ibrutinib-resistant CLL and Richter transformation","volume":"8","author":"Reiff","year":"2018","journal-title":"Cancer Discov"},{"issue":"22","key":"10.1016\/j.clml.2023.07.011_bib0070","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1182\/blood.V128.22.3232.3232","article-title":"The Bruton's tyrosine kinase (BTK) inhibitor ARQ 531 effectively inhibits wild type and C481S mutant BTK and is superior to ibrutinib in a mouse model of chronic lymphocytic leukemia","volume":"128","author":"Reiff","year":"2016","journal-title":"Blood"},{"issue":"Supp 1","key":"10.1016\/j.clml.2023.07.011_bib0071","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1182\/blood-2022-163596","article-title":"Efficacy and safety of nemtabrutinib, a wild-type and C481S-mutated Bruton tyrosine kinase inhibitor for B-cell malignancies: updated analysis of the open-label phase 1\/2 dose-expansion bellwave-001 study","volume":"140","author":"Woyach","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.07.011_bib0072","doi-asserted-by":"crossref","first-page":"S315","DOI":"10.1016\/S2152-2650(21)01746-8","article-title":"CLL-039: pirtobrutinib (LOXO-305), a next-generation, highly selective, non-covalent BTK inhibitor in previously treated CLL\/SLL: results from the phase 1\/2 BRUIN study","volume":"21","author":"Coombs","year":"2021","journal-title":"Clin Lymph Myeloma Leuk"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.07.011_bib0073","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood-2021-153856","article-title":"Pirtobrutinib (LOXO-305) is active and overcomes ERK related pro-survival signaling in ibrutinib resistant, BTK Cys481 mutant expressing WM and ABC DLBCL lymphoma cells driven by activating MYD88 mutations","volume":"138","author":"Munshi","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.07.011_bib0074","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1016\/j.clml.2018.07.081","article-title":"LOXO-305, a next generation reversible BTK inhibitor, for overcoming acquired resistance to irreversible BTK inhibitors","volume":"18","author":"Brandhuber","year":"2018","journal-title":"Clin Lymph Myeloma Leuk"},{"issue":"4","key":"10.1016\/j.clml.2023.07.011_bib0075","first-page":"212","article-title":"The emerging role of pirtobrutinib in chronic lymphocytic leukemia","volume":"20","author":"Lamanna","year":"2022","journal-title":"Clin Adv Hematol Oncol"},{"issue":"10277","key":"10.1016\/j.clml.2023.07.011_bib0076","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2023.07.011_bib0077","series-title":"Loxo@Lilly Presents Updated Pirtobrutinib Data from the Phase 1\/2 BRUIN Clinical Trial at the 2022 American Society of Hematology Annual Meeting","year":"2023"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.07.011_bib0078","first-page":"846","article-title":"Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in Richter transformation: results from the phase 1\/2 BRUIN study","volume":"140","author":"Shah","year":"2022","journal-title":"Blood"},{"issue":"suppl 16","key":"10.1016\/j.clml.2023.07.011_bib0079","doi-asserted-by":"crossref","first-page":"7513","DOI":"10.1200\/JCO.2023.41.16_suppl.7513","article-title":"Long-term safety with \u226512 months of pirtobrutinib in relapsed\/refractory (R\/R) B-cell malignancies","volume":"41","author":"Coombs","year":"2023","journal-title":"JCO."},{"issue":"9","key":"10.1016\/j.clml.2023.07.011_bib0080","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/bloodadvances.2022008447","article-title":"Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance","volume":"7","author":"Naeem","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2023.07.011_bib0081","unstructured":"Brown JR, Desikan SP, Nguyen B, et\u00a0al. Genomic evolution and resistance to pirtobrutinib in covalent BTK-inhibitor (CBTKI) pre-treated chronic lymphocytic leukemia (CLL) patients: results from the phase I\/II Bruin study 2023. Available from: https:\/\/library.ehaweb.org\/eha\/2023\/eha2023-congress\/387846\/jennifer.r.brown.genomic.evolution.and.resistance.to.pirtobrutinib.in.covalent.html?f=menu%3D16%2Abrowseby%3D8%2Asortby%3D2%2Ace_id%3D2489%2Aot_id%3D27914%2Atrend%3D4016%2Amarker%3D4176"},{"issue":"19","key":"10.1016\/j.clml.2023.07.011_bib0082","doi-asserted-by":"crossref","first-page":"14129","DOI":"10.1021\/acs.jmedchem.1c01279","article-title":"Discovery of AS-1763: a potent, selective, noncovalent, and orally available inhibitor of Bruton's tyrosine kinase","volume":"64","author":"Kawahata","year":"2021","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.clml.2023.07.011_bib0083","first-page":"62","article-title":"Pirtobrutinib preclinical characterization: a highly selective, non-covalent (reversible) BTK inhibitor","volume":"142","author":"Gomez","year":"2023","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.07.011_bib0084","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1182\/blood-2022-163268","article-title":"Kinase dead BTK mutations confer resistance to covalent and noncovalent BTK inhibitors but are susceptible to clinical stage BTK degraders","volume":"140","author":"Montoya","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2023.07.011_bib0085","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41422-018-0055-1","article-title":"PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies","volume":"28","author":"Sun","year":"2018","journal-title":"Cell Res"},{"issue":"9","key":"10.1016\/j.clml.2023.07.011_bib0086","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood-2018-07-862953","article-title":"Bruton tyrosine kinase degradation as a therapeutic strategy for cancer","volume":"133","author":"Dobrovolsky","year":"2019","journal-title":"Blood."},{"issue":"23","key":"10.1016\/j.clml.2023.07.011_bib0087","doi-asserted-by":"crossref","first-page":"15440","DOI":"10.3390\/ijms232315440","article-title":"Targeted protein degradation: clinical advances in the field of oncology","volume":"23","author":"Salama","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.07.011_bib0088","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2020-141461","article-title":"Nx-2127, a degrader of BTK and IMiD neosubstrates, for the treatment of B-cell malignancies","volume":"136","author":"Robbins","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2023.07.011_bib0089","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.3390\/cancers15051504","article-title":"Next generation BTK inhibitors in CLL: evolving challenges and new opportunities","volume":"15","author":"Frustaci","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.07.011_bib0090","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2022-164772","article-title":"NX-2127-001, a first-in-human trial of NX-2127, a Bruton's tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B-cell malignancies","volume":"140","author":"Mato","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.07.011_bib0091","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.HS9.0000845628.43637.11","article-title":"P686: a phase 1 first in-human study of bgb-16673, a Bruton tyrosine kinase protein degrader, in patients (pts) with b-cell malignancies (trial in progress)","volume":"6","author":"Tam","year":"2022","journal-title":"HemaSphere"},{"issue":"` 1","key":"10.1016\/j.clml.2023.07.011_bib0092","doi-asserted-by":"crossref","first-page":"12427","DOI":"10.1182\/blood-2022-157589","article-title":"BRUIN CLL-314: a phase III open-label, randomized study of pirtobrutinib (LOXO-305) versus ibrutinib in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"140","author":"Woyach","year":"2022","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023002306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023002306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:43:20Z","timestamp":1761871400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023002306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":92,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S2152265023002306"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.07.011","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions: Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}